NMRA
Neumora Therapeutics, Inc.
0.4757$
-0.9%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | +29.8% | +92.5% | +0.5% | +3.2% | +3.6% | +3.2% | -83.8% | -4.8% | +1.3% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -24.5% | -5.3% | +1,474.0% | -89.0% | +85.9% | -33.1% | -4.2% | +4.3% | +25.3% | +11.1% | +27.0% | -6.6% | +17.7% | +6.3% | +24.7% | -24.3% | +13.6% | -25.7% | +4.6% | +10.2% | -13.6% | -24.1% | – | |
| – | -8.2% | +60.0% | +5.6% | +14.7% | +5.9% | -3.7% | +3.4% | -10.7% | +34.6% | -4.0% | +64.2% | -26.4% | +27.4% | +6.1% | +5.4% | +6.2% | +10.4% | -18.5% | -20.5% | +13.4% | +3.3% | -9.5% | – | |
| – | -20.9% | +11.4% | +935.6% | -85.1% | +62.9% | -27.6% | -2.3% | +0.4% | +27.5% | +7.4% | +35.2% | -12.2% | +20.3% | +6.2% | +20.1% | -17.9% | +12.7% | -23.8% | -2.5% | +11.0% | -9.6% | -20.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +71.3% | +172.6% | -8.9% | -1.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -2,475.0% | – | -57.6% | – | – | -76.2% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.